Heart and Mind, published by Wolters Kluwer Medknow Publications, is a distinguished open access journal that has been serving the fields of Cardiology, Clinical Psychology, Neurology, and Psychiatry since its inception in 2017. With an ISSN of 2468-6476 and an E-ISSN of 2468-6484, this journal aims to bridge the rapidly evolving intersection between cardiovascular health and mental well-being. Based in India, it has gained recognition reflected by its Category Quartiles standing in Q3 across multiple disciplines, demonstrating its relevance and contribution to ongoing research. Researchers, healthcare professionals, and students will find Heart and Mind a valuable resource, as it facilitates access to critical insights and innovative studies within these interconnected fields. The journal’s commitment to open access ensures that vital findings and advancements are available to a global audience, fostering collaboration and knowledge-sharing to advance healthcare practices. Emphasizing high-quality research, Heart and Mind continually strives to elevate the understanding of cardiovascular and mental health, making it a pivotal platform for contemporary academic discourse.

PSYCHOPHARMACOLOGY is a leading peer-reviewed journal specializing in the field of pharmacology, specifically focusing on the effects of drugs on behavior, cognition, and emotion. Published by Springer, this esteemed journal has established itself as a pivotal resource for researchers and professionals since its inception in 1959, maintaining its relevance and rigor in the ever-evolving landscape of psychopharmacological research. With an impressive impact factor and ranking in the top quartile (Q1) of the Pharmacology category in 2023, it consistently publishes high-quality studies that contribute to both academic inquiry and clinical practice. The journal's scope includes original research, theoretical papers, and reviews, fostering a multidisciplinary dialogue among psychologists, psychiatrists, pharmacologists, and neuroscientists. As the field of psychopharmacology continues to grow, PSYCHOPHARMACOLOGY remains dedicated to disseminating innovative findings, operationalizing complex concepts, and enhancing the understanding of drug mechanisms and their implications for mental health. This commitment to excellence positions PSYCHOPHARMACOLOGY as an indispensable tool for those seeking to advance their knowledge and research in pharmacology.

Frontiers in Psychiatry is a leading journal dedicated to advancing research within the field of psychiatry and mental health. Published by FRONTIERS MEDIA SA, the journal has established a commendable reputation since its inception, reflected in its Q1 status in the 2023 Psychiatry and Mental Health category and a robust ranking of 142 out of 567 in the Scopus database. With an open access model initiated in 2009, Frontiers in Psychiatry aims to disseminate high-quality research to a global audience, fostering collaboration and innovation among researchers, clinicians, and students alike. The journal covers a broad spectrum of topics, including neurobiology, psychosocial factors, treatments, and public health implications of mental disorders, ensuring comprehensive representation of contemporary psychiatric science. Located in Lausanne, Switzerland, and running until 2024, the journal not only emphasizes the importance of mental health research but also encourages interdisciplinary discourse, making it an essential resource for anyone invested in the well-being of individuals and communities alike.

Biological Psychiatry: Global Open Science is a prestigious journal published by Elsevier, focusing on the field of psychiatry and mental health. With an ISSN of 2667-1743 and an E-ISSN of the same number, this journal has quickly established itself as a vital resource for researchers, clinicians, and students seeking to enhance their understanding of biological underpinnings in psychiatric disorders. Launched in 2021, the journal has achieved a remarkable Q1 ranking in the Psychiatry and Mental Health category by 2023, underscoring its commitment to high-quality, impactful research. Although currently operating without an open access model, it aims to provide a platform for innovative studies and breakthroughs that advance the global discourse in mental health. The journal is especially relevant for those interested in the latest developments, as it is aligned with the growing emphasis on evidence-based practice and the integration of biological findings into psychiatric care. With an H-Index reflecting its ongoing influence and relevance, Biological Psychiatry: Global Open Science is poised to become a cornerstone publication for those dedicated to the advancement of mental health research.

Brain and Behavior is a premier open-access journal published by WILEY, dedicated to advancing the field of Behavioral Neuroscience. With its ISSN 2162-3279, the journal has established itself as a vital resource for researchers, professionals, and students alike, fostering the dissemination of cutting-edge research since its inception in 2011. Renowned for its rigorous peer-review process, it enjoys a commendable Q2 ranking within the field, reflecting its impactful contributions and relevance in the scientific community. The journal not only emphasizes innovative studies that bridge behavioral science and neuroscience but also serves as a platform for diverse methodologies and interdisciplinary approaches. Accessible [open access](https://onlinelibrary.wiley.com/journal/21623279), Brain and Behavior invites submissions that explore the neural mechanisms underlying behavior, aiming to engage a global audience eager to expand the boundaries of knowledge in this dynamic field. Positioned in the heart of the United States, at 111 River St, Hoboken, NJ, it is strategically placed to collaborate with leading institutions and researchers worldwide.

SCHIZOPHRENIA BULLETIN, published by Oxford University Press, stands as a leading journal in the field of psychiatry and mental health, particularly focusing on the complexities of schizophrenia. Established in 1973, this esteemed journal covers a wide spectrum of research areas, including clinical findings, neurobiology, epidemiology, and treatment approaches, making it indispensable for researchers and practitioners alike. With its current status in the Q1 category of the psychiatry and mental health disciplines, and a remarkable Scopus rank of #34 out of 567, the journal enjoys a strong impact factor, emphasizing its contribution to advancing knowledge in mental health. Although it operates on a subscription model, the significance of the journal in disseminating groundbreaking research makes it a vital resource for those committed to improving outcomes in schizophrenia. Through its rigorous peer-review process and commitment to high-quality scientific communication, SCHIZOPHRENIA BULLETIN continues to be at the forefront of psychiatric research and discourse.

JOURNAL OF PSYCHIATRY & NEUROSCIENCE, published by the CMA-Canadian Medical Association, serves as a pivotal platform for disseminating cutting-edge research in the fields of psychiatry and neuroscience. This esteemed journal, indexed with the ISSN 1180-4882 and E-ISSN 1488-2434, focuses on advancing our understanding of mental health through meticulous peer-reviewed articles, reviews, and clinical studies. With an impressive impact within the research community, it has achieved notable rankings, including Q1 in both Medicine (miscellaneous) and Psychiatry and Mental Health, as well as Q2 in Biological Psychiatry as of 2023. The journal fosters critical dialogue among scholars and practitioners by offering insights into the complexities of brain function and mental disorders, making it a fundamental resource for healthcare professionals, researchers, and students alike. Although it operates under a subscription model, its rich content continues to inform and influence the advancement of mental health science, affirming its role in bridging the gap between research and clinical practice.

NEUROPSYCHOPHARMACOLOGY is a prestigious academic journal dedicated to advancing our understanding of the intricate relationship between psychiatric disorders and pharmacological treatments. Published by SpringerNature in the United Kingdom, this leading journal has been a cornerstone in the field since its inception in 1987, with a converged publication timeline extending to 2024. With a remarkable impact factor and illustrious rankings—being positioned 19th in Psychiatry and Mental Health and 16th in Pharmacology—NEUROPSYCHOPHARMACOLOGY is recognized for its rigorous peer-reviewed research that informs clinical practice and enhances therapeutic interventions. The journal is classified in Q1 quartile categories for both Pharmacology and Psychiatry and Mental Health, highlighting its commitment to excellence. Researchers, professionals, and students are encouraged to contribute to this vital dialogue, as the journal does not currently offer open access, emphasizing the importance of curated, high-quality content. By publishing innovative studies and reviews, NEUROPSYCHOPHARMACOLOGY plays a crucial role in shaping the future of mental health treatments and understanding neurobiological mechanisms, making it an indispensable resource for those at the forefront of psychiatric research.

Alpha Psychiatry, published by AVES, stands at the forefront of mental health research and psychiatric advancements. With a commitment to disseminating high-quality and impactful studies, this journal serves as a critical platform for scholars, clinicians, and students interested in exploring the complexities of psychiatric disorders and treatment methodologies. Although the impact factor and specific scope details are still evolving, Alpha Psychiatry is dedicated to fostering interdisciplinary dialogue and promoting innovative research that tackles contemporary challenges in the field of psychiatry. As an open-access journal, it ensures that research is widely accessible, enhancing knowledge transfer and collaboration within the global scientific community. Located in Istanbul, Turkiye, the journal proudly represents a rich academic tradition, aiming to contribute significantly to the global discourse on mental health.

Schizophrenia, published by NATURE PORTFOLIO, is a pioneering open-access journal established in 2022, dedicated to advancing the scientific understanding of schizophrenia and its associated disorders. With its commitment to disseminating high-quality research without barriers, this journal aims to provide a platform for innovative studies, reviews, and meta-analyses that enhance clinical practices and therapeutic approaches. The journal is strategically located in Berlin, Germany, a hub for mental health research and innovation. By facilitating open exchange among researchers, professionals, and students, Schizophrenia aspires to be at the forefront of the global discourse on psychiatric disorders, driving forward critical advancements that can translate into improved patient care and outcomes. With a focus on promoting the latest findings in epidemiology, neurobiology, pharmacology, and psychosocial interventions, this journal is poised to become an essential resource for scholars and practitioners alike, eager to make significant contributions to the field.